Navigation Links
Biodel Inc. Announces Pricing of Public Offering
Date:2/7/2008

DANBURY, Conn., Feb. 7 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) today announced the pricing of the underwritten public offering of 3,810,000 shares of its common stock at a price to the public of $15.50 per share. Of the shares being sold in the offering, 3,260,000 shares are being issued and sold by Biodel and 550,000 shares are being sold by certain stockholders of the Company. Biodel expects to receive net proceeds from the offering of approximately $46.4 million, after deducting underwriting discounts and commissions, and estimated offering expenses. Biodel will not receive any proceeds from the sale of shares by the selling stockholders.

In addition, the selling stockholders have granted the underwriters a 30 day option to purchase up to an additional 571,500 shares of common stock to cover over-allotments, if any.

Morgan Stanley & Co. Incorporated is acting as the sole book-runner manager and J.P. Morgan Securities Inc. is acting as co-lead manager for this offering. Leerink Swann LLC and Natixis Bleichroeder Inc. are acting as co-managers.

A registration statement relating to these securities has been filed with and declared effective by the Securities and Exchange Commission. An offer will be made only by means of a prospectus. A final prospectus relating to the offering may be obtained from the Morgan Stanley & Co. Incorporated prospectus department, 180 Varick Street, New York, NY 10014, Attention: Prospectus Department, by telephone at 866-718-1649 or by emailing prospectus@morganstanley.com.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any of the securities, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Biodel In
'/>"/>

SOURCE Biodel Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board
2. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
3. Biodel to Amend June 30, 2007 10-Q to Correct Non-Cash Share-Based Compensation Expense
4. Biodel Inc. to Present at BIO InvestorForum 2007 Conference on October 11, 2007
5. Biodel Inc. to Present at Natixis Bleichroeder Hidden Gems Conference on October 8, 2007
6. Brian J.G. Pereira, M.D. Joins Biodels Board of Directors
7. Biodel to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on December 11, 2007
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)...  BioNano Genomics, Inc., the leader in genome mapping, ... chief commercial officer. Salyer has more than 20 years ... life sciences. At BioNano, Salyer will oversee the commercialization ... to assemble a comprehensive view of complex genomes to ... institutions located in the United States ...
(Date:3/26/2015)... Neogen Corporation (NASDAQ: NEOG ) announced ... of fiscal 2015, which ended Feb. 28, increased 13% ... Earnings per share in the current quarter were $0.20, ... income increased 17% over prior year to $24,142,000, or ... share, for the same period a year ago. ...
(Date:3/26/2015)... 2015 ReliantHeart, Inc., an innovative supplier ... supplier of precision transit-time flow measurement solutions, are collaborating ... the efficiency of the HeartAssist5® Left Ventricular ... experience greater mobility and peace of mind. , ... board, will draw 1/6th of the power required by ...
(Date:3/26/2015)... Ale Gicqueau, Founder and President of ... Affairs at Align Technology, on “ Conducting Postmarket Registries ... 2015 Global Conference and Exhibition on April 25th through ... During the poster presentation, Ale Gicqueau and Victor Chen ... Postmarket Registry, the requirements and resources to conduct the ...
Breaking Biology Technology:BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 2Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 3
... SAN FRANCISCO, Calif., Dec. 8 Rigel,Pharmaceuticals, Inc. (Nasdaq: ... and chief executive officer, will participate in a panel,discussion at ... Drugs and Targets for Inflammation and Rheumatology", will take,place on ... Westin Times,Square Hotel in New York City. , ...
... endpoint of non-inferiority to Pegasys (peginterferon alfa-2a) in the ACHIEVE ... hepatitis C - , , ... serious adverse events, severe adverse events and discontinuations due to ... , ROCKVILLE, Md., Dec. 8 Human Genome ...
... ATSI ), manufacturer and marketer of state-of-the-art cardiac surgery,products and ... of the ATS 3f(R) Aortic Bioprosthesis that includes a new ... , (Logo: ... the ATS 3f Aortic Bioprosthesis PMA was approved on October ...
Cached Biology Technology:Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 2Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 3Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 4Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 5Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 6Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 7Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 8Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 9ATS Medical Provides Update on US Commercialization of Its ATS 3f Aortic Bioprosthesis 2ATS Medical Provides Update on US Commercialization of Its ATS 3f Aortic Bioprosthesis 3
(Date:3/12/2015)... VIEW, Calif. , March 12, 2015 /PRNewswire/ ... with Complimentary Registration here: http://bit.ly/1G7Os0L . SPEAKERS: ... Manager Aravind SeshagiriPhoto - http://photos.prnewswire.com/prnh/20150311/181111 ... in order to compete in several different markets ... market is currently witnessing an uptrend. ...
(Date:3/10/2015)... -- Transforming How We Look at Medicine ... Human Space Flight" by Michael A. Schmidt ... was recently featured by Springer Science Media, highlighting the most ... Specifically, "Personalized Medicine in Human Space Flight" was among ... and 2014 from Springer in the journal Metabolomics ...
(Date:3/4/2015)... 04, 2015 Research and Markets ... the "Global Biometrics Market Forecast and Opportunities, ... The market for biometric authentication systems is projected ... till 2020 The driving forces for ... needs, government projects and constant development in technology. ...
Breaking Biology News(10 mins):Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3
... Researchers are delving into abnormal gene function in mitochondria, ... the place where energy is generated from the most ... to life, defects in mitochondria may affect a wide ... Some names of mitochondrial disorders are Leigh,s disease, ...
... research, published this week in Chemical Communications , ... insects, ability to detect plants by interfering with their ... by insect pests and contribute to food security. ... institute of BBSRC said: "One way in which insects ...
... that a University of Utah cardiologist proposes as a cause ... National Institutes of Health (NIH) likes to seeand reward with ... Pioneer Award. Ivor J. Benjamin, M.D., professor of internal ... of Cardiovascular Research at the U of U School of ...
Cached Biology News:How mitochondrial gene defects impair respiration, other major life functions 2How mitochondrial gene defects impair respiration, other major life functions 3Scientists discover how to send insects off the scent of crops 2Groundbreaking model of heart disease rewarded with NIH Pioneer Award 2Groundbreaking model of heart disease rewarded with NIH Pioneer Award 3
Anti 7H6 Antigen (tight-junction associated protein Antigen) Monoclonal Antibody 7H6...
... Rabbit Antibody to ARG. Vasopressin ... vasopression peptide. Cells are found in ... fibers are found throughout the hypothalmus ... perfused tissue. Immunogen: ...
Rabbit polyclonal to LCAT ( Abpromise for all tested applications). entrezGeneID: 3931 SwissProtID: P04180...
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
Biology Products: